2 recruiting, 1 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Higher-Risk Myelodysplastic Syndrome: new trials by email Literature Review of Higher-Risk Myelodysplastic Syndrome trials Research Report on Higher-Risk Myelodysplastic Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) GEN3018 - R/R AML, R/R HR-MDS | Phase 1 | Recruiting | Genmab | 78 | 2026-02-16 | 2026-10-27 |
| Study of 3D189 in Patients With Hematologic Malignancies 3D189 - Acute Leukemia, Multiple Myeloma | Phase 1 | Completed | 3D Medicines | 16 | 2022-08-01 | 2026-09-09 |
| Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies CCS1477, Pomalidomide, Dexamethasone - Haematological Malignancy, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | CellCentric Ltd. | 250 | 2019-08-09 | 2026-06-24 |
Leukemia, Myeloid, Acute (2) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Hematologic Neoplasms (1) · Lymphoma, T-Cell, Peripheral (1)
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Hemorrhagic Disorders (2) · Hemostatic Disorders (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, Myeloid (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoproliferative Disorders (2)
Azacitidine (1) · Bortezomib (1) · CCS1477 (1) · Dexamethasone (1) · Lenalidomide (1) · daratumumab (1) · ixazomib (1) · pomalidomide (1) · venetoclax (1)
3D Medicines (1) · CellCentric Ltd. (1) · Genmab (1)
Spain (2) · China (1) · Denmark (1) · France (1) · Italy (1) · Sweden (1) · United Kingdom (1) · United States (1)
Tim Somervaille (1)
2025 (1)